GC Pharma (Formerly known as Green Cross)
107, Ihyeon-ro 30beon-gil
Giheung-gu
Yongin-si
Gyeonggi-do
United States
Tel: 82-31-260-9300
Fax: 82-31-260-9413
Website: http://www.greencross.com/
Email: info@greencross.com
22 articles with GC Pharma (Formerly known as Green Cross)
-
GC Pharma Reports Full Year 2018 Results
2/12/2019
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2018.
-
CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome
1/7/2019
CANbridge Pharmaceuticals Inc. announced an exclusive licensing agreement in the greater China area to commercialize Hunterase™, a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy for the treatment of Hunter syndrome.
-
GC Pharma Reports Q3 2018 Results
10/30/2018
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months ended September 30, 2018.
-
GC Pharma Receives Korea's MFDS Approval of GCFLU Quadrivalent (Influenza Vaccine) for persons 6 months and older
10/1/2018
GC Pharma announced today it has received approval from the South Korean Ministry of Food and Drug Safety (MFDS) expanding the indication for GCFLU Quadrivalent™ (Seasonal Influenza Vaccine) to include use in persons 6 months and older. Prior to this, the vaccine was approved for use in persons 3 years of age and older.
-
GC Pharma Reports Q2 2018 Results
8/1/2018
Q2 Performance was In-line with Expectations
-
GC Pharma Reports Q1 2018 Results
4/27/2018
GC Pharma announced unaudited results for the three months ended March 31, 2018.
-
GC Pharma and Lee's Pharm Enter Into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
2/14/2018
Under the terms of the agreement, Lee's Pharm receives exclusive rights to develop and commercialise the anticoagulant for the greater China and South East Asian market.
-
GC Pharma Reports Full Year 2017 Results
2/5/2018
GC Pharma (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2017.
-
GC Pharma Confirms Phase I/III Clinical Trial of New Protein Therapy for Hepatitis B
1/18/2018
The clinical 2/3 trial is expected to take around 5 years to complete, with patient enrollment beginning in early 2018.
-
Green Cross Receives Complete Response Letter From US FDA For IVIG-SN
11/23/2016
-
US FDA Accepts Green Cross' Biologics License Application For IVIG-SN
1/26/2016
-
Green Cross To Build Cell Therapy Manufacturing Facility In China
4/29/2015
-
Green Cross To Form Cell Therapy Company In China
3/16/2015
-
President Of Leading South Korean Biopharmaceutical Company Green Cross Joins Stemedica Cell Technologies, Inc.'s Board Of Directors
4/22/2014
-
Aquavit and Green Cross Sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia
8/9/2012
-
Green Cross Gains Market Approval With the World's 2nd Orphan Drug for Hunter Syndrome in South Korea
1/27/2012
-
Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
4/21/2011
-
Biocryst Pharmaceuticals Partner Green Cross Receives Marketing & Manufacturing Approval for Peramivir in South Korea
8/16/2010
-
Biocryst Pharmaceuticals's Partner Green Cross Files for Peramivir Regulatory Approval in South Korea
1/8/2010
-
Abraxis BioScience, Inc. Announces Agreement with Green Cross for the Commercialization of ABRAXANE in Korea
11/28/2007